Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.
Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, Iser D, Ustianowski A, Kulasegaram R, Stedman C, Tu E, Grebely J, Dore GJ, Nelson M, Matthews GV.
Martinello M, et al. Among authors: orkin c.
JHEP Rep. 2023 Jul 27;5(10):100867. doi: 10.1016/j.jhepr.2023.100867. eCollection 2023 Oct.
JHEP Rep. 2023.
PMID: 37771545
Free PMC article.